Statins and SLE: To add or not to add? 💊 Abstract #0599: In an emulated target trial of patients with SLE, statin users vs non-users had significantly⬇️ risk of all-cause death in both ITT & per-protocol analyses. - No significant differences in MACE or ESKD. @RheumNow #ACR25

Plenary 1: SELECT-GCA (RCT, UPA vs PLBO in GCA) Pts in remission re-randomized at wk52 Higher maintenance of remission in pts who continued UPA15 (69%) vs switchers from UPA15->PLBO (29%) Argues strongly for continuing tx in GCA for >1yr! @RheumNow #ACR25 Ab#0776 #ACRBest https://t.co/exmmIcpgbP

• https://x.com/EBRheum/status/1982473544505372756/photo/1
• https://x.com/EBRheum/status/1982473544505372756/photo/1

Ribeiro et al. Case series of combination bDMARD/tsDMARD in PsA from Toronto. 24 patients, median just over a year follow-up. Appear effective, especially for objective skin and joint measures. No major safety concerns but short follow-up to date. @RheumNow #ACR25 Abstr#565 https://t.co/Zk3odT2EX2

• https://x.com/RichardPAConway/status/1982473041276981274/photo/1

#0775 Higher circulating microbial small RNA tDR-1 linked to lower risk of developing RA in CCP3+ individuals (AUC 0.86). tDR-1 downregulates interferon-response genes in vitro, suggesting microbiome-mediated anti-inflammatory mechanism in RA pathogenesis. @RheumNow #ACR25

#0774 Multi-omic profiling of anti-CCP3+ “at-risk” individuals reveals Tph & cytotoxic CD8+ expansions, altered gene/chromatin profiles and predictive model (AUC 0.77) for RA conversion PTPN22 locus accessibility & Tph ≥ 2.45% identify highest risk. @RheumNow #ACR25 https://t.co/JDSMkdmoGv

• https://x.com/DrMiniDey/status/1982469014984311269/photo/1

Dr. Werth on the #SLE guidelines on tx of cutaneous LE: 🔅All patients should be on hydroxychloroquine unless with CI. ☝️Important! For SLE pts presenting with new-onset rashes, review/ask about medications; consider drug-induced SCLE. #ACR25 @RheumNow https://t.co/ok5jAi7uO0

• https://x.com/RHEUMarampa/status/1982466797971386674/photo/1
• https://x.com/RHEUMarampa/status/1982466797971386674/photo/1

#ACR25 In a rush and wondering which abstract to look out for pertaining to new update on Biologics in #SLE #lupus? Please find my article on conference preview @RheumNow https://t.co/usIXPsj5bm https://t.co/4wmWvDyv83

• SLE Conference Preview: progress in biologics | RheumNow
• https://x.com/Yuz6Yusof/status/1982466449328189855/photo/1

Early, low level proteinuria is a harbinger in SLE. ~50% with elevated UPCR but <0.5 had actionable LN on early bx. Risk factor = low c3/c4 Urine biomarkers promising #ACRBest #ACR25 @RheumNow https://t.co/WuNPKeqeid

• https://x.com/Dr_Brian_MD/status/1982460596923576584/photo/1
• https://x.com/Dr_Brian_MD/status/1982460596923576584/photo/1

From Dr. Petri at Plenary - even small amounts of proteinuria are a PROBLEM. Reduction of microalbuminuria by even 10% improves mortality! #ACR25 @RheumNow https://t.co/hjmH26vXIb

• https://x.com/Dr_Brian_MD/status/1982458294351397093/photo/1

For #SLE pleuropericarditis: recommendation intentionally tries to leverage use of colchicine/NSAIDs vs. GCs But there are special situations where GCs are req’d: > Concomitant active SLE > CI to NSAIDs/Col > Recurrent pericarditis > Late pregnancy > 💊interxns #ACR25 @RheumNow https://t.co/sLL72t3Qhf

• https://x.com/RHEUMarampa/status/1982454308315484260/photo/1
• https://x.com/RHEUMarampa/status/1982454308315484260/photo/1

Year in Review: Regency Trial showed that LN pts given obinutuzumab achieved CRR at 76 wks (46.4%) vs. PBO. Take note: the Regency trial did not evaluate the extrarenal effects of Obinutuzumab in #SLE, thats for a diff study. #ACR25 @RheumNow https://t.co/WJssU1DbzZ

• https://x.com/RHEUMarampa/status/1982445925025853468/photo/1

Saphnelo (anifrolumab) has been recommended for approval in EU by CHMP for systemic lupus erythematosus (on top of standard therapy) as a once-weekly pre-filled pen. Recommendation based on TULIP-SC Phase III trial. https://t.co/UurvtLNP7S https://t.co/xeKVdVYu3z

• Positive CHMP opinion for subcutaneous Saphnelo

🔥 Hot off the press Prof John Stone shares results from Phase 3 of REPLENISH, out only a few days ago, in which secukinumab met all primary endpoints in treatment of PMR. https://t.co/RlcQWybKrR #ACR25 @RheumNow https://t.co/ucNt2HxJpW

• REPLENISH - Secukinumab Works in Polymyalgia Rheumatica | RheumNow
• https://x.com/DrMiniDey/status/1982143397759467619/photo/1

Summary of updates in Vasculitis by Dr John Stone: 1. Anti-CD19 in IgG4Rd, 2. IL6 6R blockade in GCA/IL17i in PMR, 3. IL5RA+ ritux in EGPA. CART in AAV? @RheumNow #ACR2025 https://t.co/HxPNRE98Vl

• https://x.com/MartinezZayasMd/status/1982147567065371058/photo/1